Skip to main content

Table 1 An overview of patient measurements

From: Clinical evaluation of respiration-induced attenuation uncertainties in pulmonary 3D PET/CT

 

Affected lung

Tumour SUV max

Tumour size (CC)

Motion amplitude tumour (mm)

∆CT number (EI-EE) (Lung ROI)

∆SUV max (EI-EE) (Tumour)

∆SUV max (3D-phase) (Tumour)

∆SUV mean (EI-EE) (Lung ROI)

∆SUV mean (3D-phase) (Lung ROI)

∆SUV mean (EI-EE) (Muscle ROI)

∆SUV mean (3D-phase) (Muscle ROI)

#1

Right

15.1

94.0

1.7

−3.6%

0.3%

−5.4%

−0.5%

0.2%

0.0%

0.2%

#2

Right

18.2

79.4

1.4

−21.8%

−3.9%

−0.3%

−4.1%

−4.0%

0.4%

2.7%

#3

Right

19.9

22.4

2.8

−10.2%

−1.3%

0.6%

−1.8%

4.9%

0.7%

1.3%

#4

Right

11.1

30.9

1.4

−20.2%

−2.4%

−1.0%

−4.1%

−1.3%

1.0%

1.9%

#5

Right

23.4

15.5

3.3

−4.5%

1.3%

−1.7%

−0.6%

1.8%

0.0%

4.5%

#6

Left

2.7

12.2

5.5

−14.0%

−5.4%

1.5%

−2.8%

1.3%

0.1%

3.0%

#7

Right

3.6

1.3

2.0

−14.6%

−5.8%

0.3%

−4.3%

5.2%

−1.5%

0.1%

 

Right

11.1

1.0

2.0

-

−7.7%

−8.4%

-

-

-

-

#8

Left

14.2

17.7

7.3

−29.0%

−8.4%

−2.6%

−8.1%

−1.7%

−0.2%

0.8%

#9

Left

14.5

19.8

16.4

−21.0%

−9.3%

−8.8%

−8.0%

−5.7%

−1.4%

8.2%

#10

Right

9.8

2.2

8.6

−12.8%

−7.6%

1.4%

−3.1%

−0.5%

0.2%

0.0%

#11

Right

24.8

33.7

1.7

−25.6%

−2.0%

−1.1%

−5.0%

−0.6%

0.8%

3.6%

#12

Left

24.1

94.1

1.7

−29.7%

−4.5%

−0.4%

−12.2%

−3.6%

0.7%

1.5%

#13

Right

5.9

3.0

6.6

−12.9%

−5.4%

3.0%

−2.8%

2.0%

−1.1%

1.6%

 

Right

3.7

8.9

5.7

-

−6.2%

2.8%

-

-

-

-

#14

Left

10.8

25.5

5.2

−17.9%

−5.3%

−3.6%

−4.8%

3.8%

1.5%

−2.7%

#15

Right

13.6

23.4

27.1

−20.6%

−9.5%

−2.5%

−8.0%

−0.3%

−1.4%

−0.4%

#16

Right

12.0

23.0

4.1

−8.9%

−6.9%

4.8%

0.5%

−18.5%

−0.5%

1.1%

#17

Right

7.5

18.8

4.2

−23.3%

−7.8%

−0.5%

−3.1%

1.9%

1.2%

−0.7%

#18

Left

3.0

4.9

1.4

1.3%

0.2%

0.2%

0.4%

1.2%

0.3%

1.9%

#19

Left

3.4

2.9

12.7

−18.2%

−5.8%

−21.1%

−2.2%

−6.7%

1.8%

4.0%

#20

Left

10.7

3.3

6.5

−13.0%

−3.9%

−3.7%

−2.7%

0.7%

−0.6%

1.3%

#21

Left

17.2

6.2

2.0

−15.1%

−1.2%

−1.1%

−4.7%

−0.7%

0.6%

0.9%

#22

Left

7.5

1.9

2.4

−5.7%

−0.2%

1.0%

1.6%

2.1%

1.2%

2.6%

 

Right

7.1

1.9

13.4

−19.5%

−5.7%

−4.2%

−1.6%

1.7%

0.8%

2.9%

#23

Left

4.0

2.0

2.2

−11.4%

−0.6%

5.9%

−2.1%

−0.1%

−1.9%

−2.1%

 

Right

9.0

2.0

2.4

−12.8%

−6.0%

0.7%

−1.4%

−4.0%

−1.1%

−6.8%

#24

Right

16.2

13.2

8.2

−18.6%

−2.5%

−3.7%

−2.3%

−1.0%

−0.5%

−0.2%

#25

Right

9.5

16.5

2.4

−18.0%

−9.2%

−8.4%

−3.8%

−0.1%

−0.3%

1.9%

#26

Right

5.3

5.6

9.0

−13.9%

−3.2%

6.2%

−2.1%

−2.3%

0.7%

−1.2%

 

Right

3.7

2.3

5.1

-

−1.0%

0.4%

-

-

-

-

 

Left

4.9

2.4

3.5

−18.1%

−3.2%

0.7%

−3.7%

−0.7%

0.7%

0.9%

#27

Left

16.9

17.5

1.4

−23.2%

−1.9%

−2.7%

−9.6%

1.1%

0.6%

1.6%

#28

Left

26.2

21.5

4.4

−15.4%

−1.5%

−2.8%

−2.0%

0.4%

0.6%

0.5%

#29

Right

23.9

25.0

1.4

−18.3%

−3.0%

−4.8%

−4.6%

2.2%

0.0%

3.0%

#30

Right

5.2

1.8

7.9

−5.4%

−6.7%

−4.1%

−0.1%

−5.5%

0.7%

2.4%

#31

Left

15.4

3.1

5.7

−18.3%

−3.2%

3.0%

−5.3%

−5.6%

−0.3%

5.2%

#32

Left

3.7

4.8

2.0

−11.5%

−1.4%

1.7%

−1.8%

−1.3%

0.0%

1.8%

Mean

 

11.5

17.5

5.3

−15.6%

−4.1%

−1.6%

−3.5%

−1.0%

0.1%

1.4%

STDEV

 

7.0

23.4

5.1

7.0%

3.0%

4.8%

3.0%

4.2%

0.9%

2.5%

Min

 

2.7

1.0

1.4

−29.7%

−9.5%

−21.1%

−12.2%

−18.5%

−1.9%

−6.8%

Max

 

26.2

94.1

27.1

1.3%

1.3%

6.2%

1.6%

5.2%

1.8%

8.2%

T-test significance

     

5.56E-08

0.0036

4.1E-06

0.13

0.52

0.0062

  1. An overview with the individual patient measurements. For the SUV values, we also determined the significance level, with the null hypothesis that they were the same, using a two-tailed paired Student's T-test. When two tumours are present in the same lung, the measurements of that lung are only provided once.